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Background: Although African ancestry represents a significant risk factor for prostate cancer, few studies have
investigated the significance of prostate cancer and relevance of previously defined genetic and epidemiological
prostate cancer risk factors within Africa. We recently established the Southern African Prostate Cancer Study
(SAPCS), a resource for epidemiological and genetic analysis of prostate cancer risk and outcomes in Black men
from South Africa. Biased towards highly aggressive prostate cancer disease, this is the first reported data analysis.
Methods: The SAPCS is an ongoing population-based study of Black men with or without prostate cancer. Pilot
analysis was performed for the first 837 participants, 522 cases and 315 controls. We investigate 46 pre-defined
prostate cancer risk alleles and up to 24 epidemiological measures including demographic, lifestyle and environmental
factors, for power to predict disease status and to drive on-going SAPCS recruitment, sampling procedures and
research direction.
Results: Preliminary results suggest that no previously defined risk alleles significantly predict prostate cancer
occurrence within the SAPCS. Furthermore, genetic risk profiles did not enhance the predictive power of prostate
specific antigen (PSA) testing. Our study supports several lifestyle/environmental factors contributing to prostate
cancer risk including a family history of cancer, diabetes, current sexual activity and erectile dysfunction, balding
pattern, frequent aspirin usage and high PSA levels.
Conclusions: Despite a clear increased prostate cancer risk associated with an African ancestry, experimental data
is lacking within Africa. This pilot study is therefore a significant contribution to the field. While genetic risk factors
(largely European-defined) show no evidence for disease prediction in the SAPCS, several epidemiological factors
were associated with prostate cancer status. We call for improved study power by building on the SAPCS resource,
further validation of associated factors in independent African-based resources, and genome-wide approaches to
define African-specific risk alleles.
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To-date, there is little evidence implicating any carci-
nogens or modifiable risk factors to prostate cancer
development and subsequent progression. Furthermore,
there is currently no known cure for metastatic disease.
Henceforth, the greatest hope of minimizing the impact
of prostate cancer is early detection and intervention. A
major consequence of this approach however, is the
potential for over-diagnosis and over-treatment of indi-
viduals whose disease may never eventuate to mortality.
Regular screening in developed nations for the most
commonly used marker of prostate cancer to-date, pros-
tate specific antigen (PSA) levels has become somewhat
controversial. Risk stratification studies within Europe
and the USA [1-3] have prompted recommendations
from both the American Urological Association and
American Cancer Society to only screen men with a
life-expectancy exceeding 10 years. Furthermore, the
U.S. Preventive Services Task Force have removed their
recommendation for regular PSA screening of asymp-
tomatic men, regardless of age [4]. The heterogeneous
nature of prostate cancer and the potential of indirect
influences affecting PSA levels, has prompted investigations
into alternate prognostic marker development, particularly
the early detection of aggressive disease. AlternativeFigure 1 Current content of prostate cancer risk alleles. (A) Chromoso
risk alleles achieving genome-wide significance (P-value < 10-6). Each dot re
numerical value indicates the number of SNPs that dot represents (applicab
discovery population of each SNP. (B) Classification of each SNP representemarkers such as prostate cancer antigen 3 (PCA3) [5] and
several genetic risk profiles [6,7] have been proposed to
compliment PSA screening methods, but these methods
are still being fine-tuned for clinical application.
In addition to increasing age and a familial history of
the disease, an African ancestry is one of the few known
risk factors of prostate cancer [8-14]. Despite this fact,
prostate cancer genome-wide association studies (GWAS)
have to-date been predominantly European biased. As of
October 2012, a total of 94 single nucleotide polymor-
phisms (SNPs) across 41 chromosomal loci were reported
to achieve a genome-wide significance level, which we
conservatively define in this report as a p-value < 10-6 in
order to maximize capture of potential loci, across 18
GWAS (Figure 1 and Additional file 1: Table S1). Of the
18 GWAS, a total of 15 (83%) were performed within a
European (including one Latin American [15]) study
population, two on a Japanese cohort [16,17] and a single
GWAS has exclusively targeted African American’s [18].
European study bias is not only evident by the dispro-
portionate focus of GWAS discoveries in European men
(77/95; 81%), but also in the current content of popular
genome-wide arrays, which best represent individuals of
European (53-93% genomic coverage dependent on array
size) and East Asian (55-92% coverage) ancestry and to amal distribution and discovery population of published prostate cancer
presents one single nucleotide polymorphism (SNP), except where a
le to regions 8q24 and 17q12). Dots are color coded to represent the
d in Figure (A), relative to known, characterized genes.
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[19]. The more recent release of 2.5 and 4–5 million
marker arrays has improved rare variant content but not
shown a marked improvement in Yoruba genomic
coverage (approximately 71% coverage).
Due to the predicted complexity of prostate cancer,
epidemiological factors including occupational hazards
[20,21], dietary factors and other health related issues
(reviewed in [22]), as well as several hormone influenced
conditions such as male pattern baldness [23], have also
been proposed to play a role in prostate cancer patho-
genesis. However, investigations have similarly been
largely focused on European populations.
The goal of the Southern African Prostate Cancer Study
(SAPCS) is to provide a unique resource, un-biased
by non-African admixture or by routine PSA screening
practices of Western societies, to investigate the inherited
genetic contribution as well as epidemiological (including
environmental and lifestyle factors) influences on global
disparities in prostate cancer, particularly associated with
men of African descent. The power of this study is not only
in the comprehensive analysis of known risk factors in an
as yet un-investigated, potentially high risk population (per-
taining to a pure African ancestral contribution), but also in
the inclusion of study participants presenting overwhelm-
ingly with an aggressive disease phenotype. This is the first
analysis of genetic and epidemiological data within the
SAPCS and the first study of its kind for Black South
African men.
Methods
Study design and inclusion
All men contributing to the SAPCS in this report are
defined as Black South African’s, specifically they all self-
defined as Southern Bantu speakers, a term used to
group the majority of Bantu languages spoken in South
Africa, Botswana and Mozambique. Although we re-
cognize that it is grammatically correct to use prefixes
when referring to a Bantu people or language, for simpli-
city, in this report, we will refer to participating Southern
Bantu groups by the English derived ethno-linguistic iden-
tifiers. The population contributions and substructure of
the SAPCS participants, the latter based on genome-wide
genetic analysis, is defined elsewhere [Tindall et al., sub-
mitted]. We recognize a unique within Africa Southern
Bantu population clustering.
The SAPCS is an ongoing longitudinal collection initiated
in 2008 with approval by research ethics and institutional
review boards at the Limpopo Provincial Government
and University of Limpopo, South Africa (#32/2008 and
MREC/H/28/2009), University of Pretoria, South Africa
(#43/2010), J. Craig Venter Institute, U.S.A. (#2010-129)
and the University of New South Wales, Australia
(#H00/088). As recruitment is ongoing, this manuscriptpresents research performed at the first three stages of
collection as outlined in Figure 2. Participants have to-
date been sourced from urological clinics within South
Africa including, Polokwane Hospital, Tshilidzini Hospital,
Pretoria’s Steve Biko Academic Hospital (SBAH) and the
Medical University of South Africa (MEDUNSA), repre-
senting both rural and urban based clinics respectively. As
routine PSA testing is not common practice in these re-
gions, study participants presented at the clinic largely as
a result of urological complaints. Subjects were reviewed
by local urologists, PSA testing performed, and prostate
cancer status defined histopathologically by Gleason score
and tumor grade (well, moderate and poor differentiation).
Control samples were those diagnosed with either benign
prostatic hyperplasia (BPH) and/or absence of any clinic-
ally definable prostate cancer. A clinical and demographic
summation of patients and controls within the SAPCS has
been presented elsewhere, including the evolution and
cultural limitations of establishing a prostate cancer study
within the constraints of Africa [Tindall et al., submitted].
As of April 2010 (stage 1) there were 323 participants, 179
cases and 144 controls, by October 2011 (stage 2) the
study totaled 503 subjects, 297 cases and 206 controls,
and was largely restricted to four ethnolinguistic popula-
tions (the Pedi, Tsonga, Venda and Tswana) and by the
time of data analysis (stage 3) the study had been ex-
panded to include all peoples defined as Southern Bantu
and included 837 participants, 522 cases and 315 controls.
Pilot analysis allows for assessing recruitment validity as
well as providing statistical trends to drive future research
focus.
Study material and data collection
From each participant, a minimum of 800 ng DNA was
extracted from whole blood using Qiagen QIAmp DNA
mini kits. Participants were also requested to complete a
questionnaire during a face-to-face interview with an at-
tending professional urologist or nurse. A summary of
the questionnaire will be made available on the study
webpage at www.SAPCS.Webs.com.
SNP selection
All SNPs reported to reach genome-wide significance,
defined here as a P-value < 1x10-6, and published prior
to April 2010 were included in our preliminary stage 1
analysis (44 SNPs; Figure 1 and Additional file 1: Table
S1). Two additional SNPs included, Bd11934905 (8q24
region 2), which did not achieve genome-wide signifi-
cance (P-value = 1.5x10-4) in the discovery target study,
but was unique in the African American population [24]
and rs7210100 (17q21), which achieved genome-wide
significance in the first published African American
prostate cancer GWAS (P-value = 3.4x10-13), but was
published after the stage 1 publication deadline [18].
Figure 2 Stages 1 to 3 of SAPCS data analysis. Depicting study size, study inclusion (Bantu population groups and participating urological
clinics), data analysis and study power at first three stages of SAPCS collection. *Study Power represents power to detect an OR = 1.4, given a
probability of exposure in controls = 0.1 in single hypothesis testing.
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Stage 1 genotyping was performed using a custom de-
signed Illumina Universal Array Matrix (UAM). Quality
control (QC) inclusion values were a GenTrain score > 0.5
and a call rate > 0.9 (SNP and sample). The rs7210100
variant was genotyped via direct Sanger sequencing. SNPs
regarded as significant (P-value ≤ 0.05) prior to correction
for multiple testing, were genotyped on additional samples
(stage 2) also via direct Sanger sequencing. Primer infor-
mation and amplification conditions are available upon
request.
Statistical analysis
For disease association testing we report Fischer’s exact
P-value, per allele odds ratios (OR) and 95% confidence
intervals (CI) estimated by logistic regression using SVS
version 7. Q-values, generated using a ‘smoothing’ method
suggested by Storey and Tibshirani [25] provide signifi-
cance levels adjusted for multiple testing by correcting for
false discovery rate are generated using the QVALUE soft-
ware package on R. Genotype-phenotype interactions
were assessed for variants genotyped in stage 2 analysis
using logistic regression models. Phenotypic characteris-
tics applicable to both cases and controls, including PSA
levels and family history of prostate cancer and all cancers
combined were assessed in both cases and controls com-
bined. Characteristics applicable only to prostate cancer
cases, including age at presentation, Gleason score and
tumor grade, were assessed in cases samples only. The ef-
fect of risk alleles on PSA levels, were further controlled
for age as a potential confounding factor to this pheno-
type. Q-values for this subset of variants (thus a reducednumber of hypothesis tested) were generated using the
Benjamini and Hochberg method [26]. Power calculations
were performed using PS Power and Sample Size Calcula-
tion version 3.0.43.
Genetic risk scores (GRS) were calculated using three
alternative risk models (Addition file 2: Figure S1) for 3,
6 and 38 SNPs each. The 38 SNPs represent all stage 1
genotyped SNPs that passed QC, 6 SNPs represent all
stage 2 genotyped SNPs and 3 SNPs represent SNPs that
achieved an un-corrected P-value < 0.05 in stage 2 ana-
lysis. Models 1 and 2 are derived as a count of risk al-
leles. Model 1, count GRS (cGRS), reflects the number
of risk alleles only (cGRS = ∑risk alleles), and Model 2,
weighted GRS (wGRS), is weighted according to the
population specific allelic ORs (wGRS = LN OR∑risk
alleles). Model 3 calculates the risk of each genotype
combination (OR^n risk alleles) relative to the average
population risk (∑population frequency x genotypic risk)
in this case, SAPCS control population. Receiver Operat-
ing Characteristic (ROC) curves were generated to
evaluate the performance of each genetic risk model and
area under the curve (AUC) calculated to estimate the
predictive power of each model [27]. We further assess
the impact of combining PSA measures and the most
accurate GRS presented here, wGRS for 38 SNPs.
Associations between prostate cancer status and vari-
ous epidemiological parameters were first assessed by
crude analysis using Pearson’s Chi-squared test with Yates’
continuity correction for dichotomous variables or Welch
two sample T-test comparing means in continuous vari-
ables. Multiple logistic regression was also performed on
each variable accounting for confounders including age,
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tion group. Where a parameter contains >2 response vari-
ables, the condition most equally represented in both
cases and controls was used as the reference. Further-
more, we performed multinomial logistic regression ana-
lysis to assess possible associations between various
clinical features including Gleason score and tumor grade.
Results
Stage 1: Genotype analysis
We recently described the Southern Bantu population
groups included in this study as forming a single genetic
cluster distinct from other African populations including
both Eastern and Western Bantu-derived populations,
supporting the combined analysis of Southern Bantu men
for genetic association studies [Tindall et al., submitted].
We genotyped a total of 46 SNPs for stage 1 analysis (183
cases and 146 controls). Four case samples (two Pedi and
one each Tsonga and Venda) and two control samples
(both Tsonga) failed to achieve a call rate > 0.9 so were ex-
cluded (leaving a total of 179 cases and 144 controls).
Eight variants failed QC parameters, including rs7000448,
rs10993994, rs8102476, rs12500426, rs1016343 (call
rate < 0.9), rs620861 (GenTrain score < 0.5) and two vari-
ants, rs12621278 and rs6983267, presented with a minor
allele frequency (MAF) = 0. Of the remaining 38 SNPs, six
achieved a P-value ≤ 0.05 prior to correcting for multiple
testing; rs10090154-T (OR = 0.55 95%CI 0.36-0.83; P-
value = 0.0044), rs6983561-C (OR = 1.54 95% CI 1.12-2.13;
P-value = 0.0094), rs13254738-C (OR = 0.70 95% CI 0.50-
0.96; P = 0.0306), rs1859962-G (OR = 1.50 95% CI 1.03-
2.20; P = 0.0379), rs1465618-A (OR = 1.80 95% CI 1.02-
3.16; P = 0.0423), and rs4242382-A (OR = 0.07 95% CI
0.50-1.00; P = 0.0503) (Table 1 and Additional file 1:
Table S1). After correcting for false discovery rate, Q-
values were all >0.05. Four of the six SNPs with un-
adjusted P-values ≤ 0.05 lie within the 8q24 region
(rs10090154, rs6983561, rs13254738, and rs4242382), one
within 17q24 (rs1859962) and one at 2p21 (rs1465618). Of
note is that the T allele of rs10090154 showed a protectiveTable 1 Stage 1 and 2 genotype results for SNPs achieving un
Stage 1 (179 cases, 144 contro
Marker
(risk allele)
Location MAF cases MAF controls OR (95% C
rs6983561 (C) 8q24 region 2 0.478 0.372 1.54 (1.12-2.
rs1859962 (G) 17q24 0.270 0.197 1.50 (1.03-2.
rs13254738 (C) 8q24 region 2 0.331 0.416 0.70 (0.50-0.
rs10090154 (T) 8q24 region 1 0.138 0.226 0.55 (0.36-0.
rs4242382 (A) 8q24 region 1 0.253 0.325 0.07 (0.50-1.0
rs1465618 (A) 2p21 0.118 0.069 1.80 (1.02-3.
Stage 1 and stage 2 association analysis with over-all prostate cancer risk was achie
lelic odds ratios (OR) and 95% confidence intervals (CI) were estimated using logist
exact test. Association results for alleles achieving un-corrected P-value < 0.05 are reffect in our study (OR = 0.55, 95% CI 0.36-0.83), in con-
trast to previous reports including the discovery European-
based GWAS, which suggests the T allele is associated with
increased prostate cancer risk (OR = 1.67) [28].
Stage 2: Follow-up genotype and genetic risk score analysis
Six variants achieving an un-corrected P-value ≤ 0.05 in
Stage 1, were genotyped on additional stage 2 samples,
for a combined study size of 503 (297 cases and 206
controls). Only three SNPs achieved un-adjusted P-
values < 0.05 in stage 2 analysis; rs6983561 (OR = 1.45
95% CI 1.15-1.92; P = 0.0024), rs1859962 (OR = 1.42 95%
CI 1.05-1.93; P = 0.0276), and rs13254738 (OR = 0.75
95% CI 0.58-0.98; P = 0.0363; Table 1 ‘Stage 2’).
Interaction between the six variants genotyped in stage
2 analysis and various clinical and demographic charac-
teristics reveals an unadjusted significant association be-
tween the C-allele of rs6983561 and serum PSA levels
above 20 μg/L (OR = 1.35, 95% CI 1.04-1.74; P-value =
0.0224). Cases defined as having a poor tumor grade
were significantly associated with rs6983561 (OR = 1.73,
95% CI 1.03-2.92; P = 0.0391) and rs1859962 (OR = 1.84,
95% CI 1.05-3.22; P = 0.0351; Table 2). Additional inter-
actions between genotype and demographic/clinical fea-
tures addressed for these SNPs include age at prostate
cancer presentation, Gleason score, family history of
prostate cancer and all cancers combined.
Three genetic risk models were applied to measure the
combined genetic risk of the various SNPs tested. For
each model the AUC, which measures the performance
of each model, improved as the number of SNPs in-
creased (Additional file 2: Figure S1A-C). This difference
was only significant for models 2 and 3 when comparing
each the 6 SNP and 38 SNP combinations to 3 SNPs.
For Model 2 the difference between AUC relative to 3
SNPs is 0.035 (95% CI 0.005-0.065, P-value = 0.0208)
and 0.065 (95% CI 0.015-0.116, P-value = 0.0117) for 6
and 38 SNPs respectively. For Model 3, the difference
between AUC relative to 3 SNPs is 0.047 (95% CI 0.005-
0.088, P-value = 0.0282) and 0.093 (95% CI 0.027-0.159,corrected P-value ≤ 0.05 in stage 1 analysis
ls) Stage 2 (297 cases, 206 controls)
I) P-value MAF cases MAF controls OR (95% CI) P-value
13) 0.0094 0.505 0.407 1.45 (1.15-1.92) 0.0024
20) 0.0379 0.260 0.199 1.42 (1.05-1.93) 0.0276
96) 0.0306 0.323 0.389 0.75 (0.58-0.98) 0.0363
83) 0.0044 0.167 0.212 0.74 (0.54-1.03) 0.0815
0) 0.0503 0.269 0.299 0.87 (0.66-1.44) 0.3189
16) 0.0423 0.098 0.081 1.23 (0.79-1.92) 0.4336
ved by comparing minor allele frequencies (MAF) in cases versus controls. Al-
ic regression models. We report un-corrected P-values derived using Fischer’s
epresented in bold type.
Table 2 Genotype-phenotype association analysis for variants genotyped in stage 2 analysis

























rs6983561 (C) 1.35 (1.04-1.74) 0.02 0.40 1.40 (0.86-2.27) 0.18 0.60 0.91 (0.51-1.62) 0.75 0.84 0.81 (0.57-1.15) 0.24 0.68 1.11 (0.72-1.71) 0.63 0.81 1.73 (1.03-2.92) 0.04 0.35
rs1859962 (G) 1.28 (0.96-1.71) 0.09 0.60 1.00 (0.61-1.65) 0.99 0.99 0.58 (0.29-1.16) 0.12 0.60 0.95 (0.64-1.42) 0.82 0.86 1.22 (0.76-1.95) 0.42 0.76 1.84 (1.05-3.22) 0.03 0.35
rs13254738 (C) 1.15 (0.87-1.52) 0.33 0.60 1.04 (0.61-1.79) 0.88 0.93 1.12 (0.67-1.89) 0.66 0.79 1.06 (0.73-1.54) 0.75 0.86 0.72 (0.46-1.13) 0.15 0.68 1.16 (0.67-1.99) 0.60 0.81
rs10090154 (T) 0.89 (0.64-1.24) 0.50 0.75 0.70 (0.34-1.43) 0.33 0.60 1.44 (0.74-2.79) 0.29 0.60 1.03 (0.64-1.65) 0.91 0.91 0.79 (0.43-1.44) 0.43 0.76 1.28 (0.66-2.47) 0.47 0.76
rs4242382 (A) 0.81 (0.61-1.09) 0.17 0.60 0.87 (0.50-1.50) 0.62 0.79 1.20 (0.66-2.18) 0.54 0.75 1.06 (0.72-1.57) 0.78 0.86 1.21 (0.74-1.96) 0.45 0.76 1.46 (0.83-2.56) 0.19 0.68
rs1465618 (A) 1.29 (0.80-2.08) 0.29 0.60 1.46 (0.68-3.16) 0.33 0.60 1.43 (0.58-3.47) 0.44 0.71 0.71 (0.39-1.29) 0.26 0.68 1.54 (0.80-2.95) 0.20 0.68 1.30 (0.56-3.01) 0.54 0.81
†Genotype-phenotype association analysis for PSA (<20 μg/L = 0, ≥20 μg/L = 1), Family PCa (defined as first degree relatives affected by prostate cancer; no = 0, yes = 1) and Family Ca (defined as first and second
degree relatives affected with any cancer; no = 0, yes = 1) was performed using all available samples (cases and controls).
¥Genotype-phenotype association analysis for Age of prostate cancer presentation (<70 yrs = 1, ≥70 yrs = 0), Gleason score (≤7 = 0, >7 = 1) and tumor Grade (well/moderate = 0, poor = 1) was performed on prostate
cancer cases only.
‡OR (odds ratios) and 95% CI (confidence intervals) were estimated using unconditional logistic regression models.
*PSA estimates were additionally controlled for Age.
§Un-corrected P-values derived using logistic regression analysis.
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2, which applies wGRS calculations, achieved a greater
AUC compared to Models 1 and 3 for all n SNP combi-
nations, although the difference was not statistically
significant (Additional file 2: Figure S1D-F). Genetic risk
Model 2 for 38 SNPs resulted in the largest AUC of all
models tested (AUC = 0.671) and was therefore evalu-
ated against the most common marker of prostate can-
cer to date, serum PSA levels, to predict prostate cancer
in this study population (Figure 3). We determine PSA
levels to be a more accurate predictor of prostate cancer
than genetic risk Model 2 for 38 SNPs, with an AUC of
0.919 (difference between areas = 0.248, 95% CI 0.176-
0.319, P-value < 0.0001). Combining the genetic risk
model presented here with serum PSA levels did not
improve the predictive capability of serum PSA alone
and actually showed a slight (though non-significant)
reduction in AUC to 0.890 (difference between areas =
0.0292, 95% CI −0.003-0.062, P-value = 0.0784).
Stage 3: Epidemiological analysis
Crude analysis of epidemiological data revealed the over-
all distribution of several variables differed significantly
between cases and controls; including population group
(P-value = 0.0046), a family history of cancer (P-value =
0.0434), previous occupation (P-value = 0.0373), presenceFigure 3 Receiver operating characteristic (ROC) curves for
genetic risk model 2 compared to PSA levels alone and
combined with genetic risk model. Genetic risk model 2 for 38
SNPs results in an AUC of 0.671. PSA levels more accurately predict
prostate cancer occurrence in the SAPCS study population with an
AUC of 0.919 (difference between areas = 0.248, 95% CI 0.176-0.319,
P < 0.0001). The predictive power of PSA was not improved when
combined with genetic risk model 2 for 38 SNPs (AUC = 0.890,
difference between areas = 0.0292, 95% CI −0.003-0.062, P = 0.0784).of diabetes (P-value = 0.0199), balding pattern (P-value =
0.0038), current sexual activity, erectile dysfunction (ED)
(P-value < 0.0001), frequent aspirin usage (P-value =
0.0003) and PSA levels (P-value < 0.0001) (Additional file
3: Table S2). Adjusted multiple logistic regression (Figure 4
and Additional file 3: Table S2) indicates a marginally in-
creased risk of prostate cancer in the Venda population
relative to the distribution of cases in the reference group
Tsonga (OR = 1.81 95%CI 1.01-3.29; P-value = 0.0473), and
relative to men who did not report any balding, men with a
combination frontal/vertex balding pattern have a signifi-
cantly greater risk of prostate cancer (OR = 1.60 95%CI
1.13-2.28; P-value = 0.0087). The association was main-
tained between prostate cancer risk and a family history of
cancer (OR = 2.60 95%CI 1.24-5.94; P-value = 0.0155), pres-
ence of diabetes (OR = 1.83 95%CI 1.13-3.01; P-value =
0.0161), present sexual activity (OR = 0.48 95%CI 0.34-0.68;
P-value < 0.0001), ED (OR = 1.53 95%CI 1.07-2.18; P-value
= 0.0187) and aspirin usage (OR = 1.68 95%CI 1.20-2.37; P-
value = 0.0026). Finally, we observe an increased risk of
prostate cancer in men with PSA levels ≥10 μg/L, com-
pared to those with a PSA < 4.0 μg/L (P-values < 0.0001).
Case-only analysis (Additional file 4: Table S3 and
Additional file 5: Table S4) revealed several associations
between variables and markers of aggressive disease includ-
ing Gleason score and tumor grade. The risk ratio of hav-
ing a Gleason score > 7 relative to <7 is decreased in Venda
compared to the reference group Tsonga (RR = 0.36 95%CI
0.15-0.89; P-value = 0.0267), decreased for cases collected
from the more urban SBAH/MEDUNSA relative to
Polokwane (RR = 0.30 95%CI 0.12-0.74; P-value = 0.0088),
decreases with increasing age (RR = 0.98 95%CI 0.94-0.99;
P-value = 0.0137), is decreased in men who report a vertex
only balding pattern (RR = 0.30 95%CI 0.10-0.95; P-
value = 0.0400) and men with a higher Gleason score
are less likely to be sexually active (RR = 0.50 95%CI 0.29-
0.88; P-value = 0.0154). Conversely, men with a Gleason
score > 7 have an increased risk of developing male breasts
(RR = 1.98 95%CI 1.13-3.49; P-value = 0.0176). We also ob-
serve a decreased risk of a history of acne (RR = 0.15 95%
CI 0.02-0.90; P-value = 0.0379), a decreased likelihood of
present sexual activity (RR = 0.49 95%CI 0.25-0.97; P-value
= 0.0395) and an increased risk of suffering ED (RR = 1.09
95%CI 0.01-1.20; P-value = 0.0322) in case samples with a
Gleason score =7 compared to <7. Although few observa-
tions were significantly associated with tumor grade (pos-
sibly due to reduced sample size), we did observe an
increased relative risk of being diagnosed with moderate
tumor grade compared to a well differentiated tumor for
men with a family history of prostate cancer (RR = 2.90
95%CI 1.14-7.43; P-value = 0.0260) and a decreased risk in
men who reported balding at a relatively younger age of
30–39 yrs compared to ≥70 yrs (RR = 0.12 95%CI 0.01-
0.98; P-value = 0.0477). Alternatively, later onset of ED was
Figure 4 Multiple logistic regression analysis for association between multiple variables and prostate cancer risk. For each variable, odds
ratios (ORs) are represented by dots and Confidence intervals (CI) are represented by horizontal lines extending from dots. Dots are color coded
according to variable groupings indicated on left hand side of Y-axis. Reference groups for variables with multiple outcomes are represented by a
single triangle (no CI) positioned along the Y-axis at X = 1. The X-axis limit was set at a value of 6.0. CI exceeding this limit are indicated by arrows.
PSA levels are not represented on this plot due to values exceeding this limit. *indicates variable is associated with over-all prostate cancer risk at
a significance level <0.05.
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1.13 95%CI 1.03-1.25; P-value = 0.0122) and poorly (RR =
1.13 95%CI 1.00-1.26; P-value = 0.0477) differentiated
tumors compared to well differentiated. Men with a PSA
level ≥100 μg/L were at an increased risk of having a
poorly differentiated tumor (RR = 6.84 95%CI 1.28-36.56;
P-value = 0.0246).Discussion
One of the most significant risk factors associated with
prostate cancer is an African ancestry. An admixture
study of prostate cancer within African Americans led to
the identification of the 8q24 prostate cancer susceptibil-
ity locus [29], arguably one of the most significant pros-
tate cancer risk loci identified to date [30]. Prostate
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becoming more prevalent yet the impact of risk alleles
within non-admixed African populations has been
largely overlooked, mainly due to logistic issues associ-
ated with establishing African-based prostate cancer
studies. We test for the first time within a unique collec-
tion of Southern Bantu prostate cancer cases as well as
geographically and age matched controls, the predictive
power of previously defined prostate cancer risk alleles
as well as several modifiable and un-modifiable epi-
demiological factors.
A major issue surrounding current diagnostic proce-
dures is the inability to determine clinically relevant pros-
tate cancer cases from indolent/benign prostatic disease.
Thus, although it could be argued that patients diagnosed
with BPH are not true, disease free controls, the inclusion
of these individuals in the SAPCS control population may
serve to eliminate possible associations with irrelevant dis-
ease status. Additionally, a study of 5068 men concluded
that presence of BPH does not increase prostate cancer
risk [31], while BPH is generally formed in transitional/
central zone of the prostate gland, while prostate cancer
within the peripheral zone [32]. As presented elsewhere
[Tindall et al., BJC, submitted], the SAPCS is biased to-
wards a more aggressive prostate cancer phenotype, dem-
onstrated by frequency of extreme serum PSA levels and
Gleason scores, compared to White and Black prostate
cancer sufferers within the USA. Lack of routine PSA test-
ing, medical infrastructure and increased use of traditional
healers all contribute to symptomatic presentation and
bias towards aggressive disease (while controlling for age
at presentation) compared to current studies based on
western practices and indolent disease presentation. The
SAPCS therefore provides a unique alternative resource to
study the impact of known genetic and epidemiological
factors driving aggressive prostate cancer disease within
Africa.
Initial association analysis of 46 SNPs within the SAPCS
revealed from 38 informative alleles a significant associ-
ation (un-adjusted) with six variants and prostate cancer
risk. After stage 2 analysis, we were able to replicate a sig-
nificant association (un-adjusted) with only three of the
previously described SNPs, namely rs6983561, rs1859962,
and rs13254738. One must caution however that our
power to detect statistical significance is hindered by a
relatively small sample size, to between 32 and 44%. A
case group >1,000 subjects would be required to achieve
80% power to detect a statistically significant (P-value <
0.05) OR ≥ 1.4 with MAF ≥ 0.2 in single hypothesis testing.
Difficulties related to achieving highly significant associa-
tions with GWAS defined prostate cancer risk alleles in
African populations has however been discussed previ-
ously [33]. As well as requiring large sample sizes to detect
significant associations in GWAS, low levels of linkagedisequilibrium in African populations may contribute to
weak associations between causal variants and SNPs that
are genotyped on GWAS platforms. Regardless, further val-
idation in a larger study is required to improve power and
more confidently reject the null hypothesis. We further
suggest that some of the significant variants (rs6983561 and
rs1859962) may be associated with clinical characteristics
of prostate cancer including serum PSA levels (rs6983561)
and tumor grade (rs6983561 and rs1859962). These results
may be indicative that there is a genetic contribution to
aggressive disease phenotype observed in these individuals.
Although efforts to decipher aggressive from indolent
disease have thus far shown limited success, recent reports
have supported an inherited component to poorer progno-
sis [34,35]. Advantages of using germline genetic markers
to decipher these individuals include, ease and accuracy of
testing, as well as being constant throughout a life-time
(non-age-dependent), hence always preceding disease and
facilitating early intervention. As no variants tested in this
study remained independently predictive after adjusting for
multiple testing and combined within a genetic risk model
showed no improvement on the predictive capability of
serum PSA testing, highlights the need for independent
prostate cancer genetic marker identification within the
context of Africa.
Although there has thus far been limited success in
identifying demographic, lifestyle or environmental influ-
ences on prostate cancer predisposition, the multi-faceted
nature of this disease is indisputable. These factors have as
yet not been explored within the context of Africa. We
provide evidence in this study for potential drivers of
prostate cancer risk within the SAPCS. While a family his-
tory of prostate cancer has been associated with increased
risk for a positive diagnosis for prostate cancer within the
USA [36], a familial link has previously been attributed
to increased screening in men with a family history of
the disease, which may contribute to this observed as-
sociation. Alternatively, results from the REDUCE
study, which boasts minimal screening bias, reported a
geographically-dependent association between prostate
cancer and a family history of the disease, yet a signifi-
cant association, regardless of geographic location, was
observed between prostate cancer and a family history
of prostate and/or breast cancer. In our study risk was
similarly not specifically attributed to a family history
of prostate cancer, but rather a history of any cancer
[37]. Where an Australian-based study reported an as-
sociation between prostate cancer and a vertex only
male balding pattern [38], the SAPCS showed a significant
association with a combination of vertex and frontal
balding, although age at onset was not a significant fac-
tor. While diabetes mellitus increases risk for most hu-
man cancers (reviewed in [39]), the impact on prostate
cancer appears largely protective [40,41], however, an
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prostate cancer patients with diabetes compared to
those without [42]. Further complicating the assessment
of this interaction is a lack of differentiating type I and
type II diabetes and the potential effect of diabetes med-
ications on prostate cancer outcome [43]. In our study
of aggressive prostate cancer disease we observed a sig-
nificant increased risk associated with pre-existing dia-
betes. In line with an Australian-based study, which
correlated increased ejaculation frequency (especially
early in life), with reduced prostate cancer risk [44] we
show a significant protective effect of increased sexual
activity and an inverse correlation with erectile dysfunc-
tion in the SAPCS. Although no association with the
presence of STDs was observed, we cannot exclude that
increased ejaculation, associated with sexual activity (or
inversely associated with erectile dysfunction), may not
be driving protection as a result of pathogenic shedding,
specifically within an environment where pathogenic
diseases are significant health concerns. Compared to a
recent report that suggests a decreased risk of prostate
cancer associated with regular use of aspirin (but not
with alternative non-steroidal anti-inflammatory drugs),
[45]], frequent aspirin use within the SAPCS was in-
versely correlated with prostate cancer. This disparity
may be impacted by the generic employment of the
term aspirin, often used to refer to any form of head-
ache medicine, including paracetemol, which exhibits
very minor anti-inflammatory activity. A unique aspect
of the SAPCS is the inclusion of both rural and more
urbanized clinic locations. The significance of the ob-
served increased prostate cancer risk associated with
men from the Venda ethnolinguistic classification
requires further investigation based on genetic and/or
environmental drivers. A potential significant environ-
mental implication for the observed association may be
based on almost 70 years of dichlorodiphenyltrichloro-
ethane (DDT) spraying for malaria control in Venda
households [46] and previous controversial association
with urogenital birth defects [47]. Interestingly, men
within a health or education related occupation were
more likely to be diagnosed with prostate cancer. The
latter could be a direct consequence of increased access
and adoption of western medical practices. Not sur-
prisingly, men with extreme PSA levels (≥20 ng/μl)
were also at an increased risk of disease. Although we
present some evidence of association between aggres-
sive disease phenotypes (high Gleason score and tumor
grade) and epidemiological characteristics, limited
study numbers (345 total cases with known Gleason
score and 305 cases with known tumor grade) reduces
the impact of any findings. Our results do however
warrant further investigation into associations with
specific population groups, geographic location, age ofprostate cancer onset, family history of cancer, sexual cap-
acity, balding pattern and age of balding, as well as devel-
opment of male breasts and acne.
Conclusions
In an attempt to use individual genetic profiles of the
SAPCS population to determine prostate cancer occur-
rence, we failed to show a significant predictive power
alone or improve correlation in combination with the
current serum PSA testing method. From these results we
suggest the current content of prostate cancer GWAS is
inadequate for predicting prostate cancer in the Southern
African Bantu study population and not suitable for im-
plementation in a clinical setting. The nature of previously
defined risk variants, which are thought to typically repre-
sent indirect associations (often in gene deserts) and a
minimal effect size (small ORs), likely contributes to the
limited impact on disease prediction we and others have
thus far observed. Current methods of GWAS are based
on the principle of LD, which is considered disadvanta-
geous in African populations known to exhibit high levels
of genetic diversity and low levels of LD [48]. Increased
haplotype diversity, is however considered beneficial for
the purpose of fine-mapping and identification of causal
variants, potentially making this cohort a valuable re-
source for defining causal variants. It is likely that new ap-
proaches in statistical imputation and next generation
sequencing technologies will not only contribute to defin-
ing true causal variants, but also better define high-risk
population groups to help identify population specific risk
loci. As we move into the era of personalized medicine,
large scale sequencing efforts will help improve current
GWAS platforms and identification of prognostic markers
via the development of population specific and disease
specific genetic profiles. Furthermore, we cannot ignore
the potential impact of demographic and lifestyle influ-
ences on prostate cancer occurrence. These pilot ana-
lyses are directing further investigative efforts as the
study leaders focus on increasing the study numbers to
achieve optimal study power. The validation of known,
specifically modifiable, risk factors calls for immediate
replication in parallel studies from within Africa. In
summary, the SAPCS provides a unique resource not
only to identify genetic determinants associated with an
African ancestry but also gene-environment interactions
in a collection of clinically relevant (aggressive) prostate
cancer cases, minimizing the impact of indolent disease
often dominant in studies from developed nations.
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Additional file 1: Table S1. Reported prostate cancer risk alleles
achieving genome-wide significance (P value < 10-6) and stage 1 genotype
association results.
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SNPs. (a) Genetic risk Model 1: Count GRS (cGRS) is defined as the total
sum of risk alleles present at each SNP (cGRS = ∑risk alleles). (b) Genetic
risk Model 2: weighted GRS (wGRS) considers both the number of risk
alleles and the OR attributed to that SNP (wGRS = LN OR∑risk alleles). (c)
Genetic risk Model 3: Risk relative to the average population is defined as
the genotypic risk (OR^n risk alleles) divided by the average population
risk (∑population frequency x genotypic risk) and calculated for each
genotype combination. All models were calculated using 38 SNPs (d), 6
SNPs that reached statistical significance in stage 1 (e) and 3 SNPs
significant in stage 2 (f). Population specific study ORs and allele
frequencies were used to calculate GRSs. For genetic risk Models 2 and 3
(b) and (c) the 6 SNP and 38 SNP combinations significantly improved
predictive power compared to 3 SNPs only. For Model 2 the difference
between AUC = 0.035 (95% CI 0.005-0.065, P = 0.0208) and 0.065 (95% CI
0.015-0.116, P = 0.0117) for 6 and 38 SNPs respectively. For Model 3, the
difference between AUC = 0.047 (95% CI 0.005-0.088, P = 0.0282) and
0.093 (95% CI 0.027-0.159, P = 0.0061) for 6 and 38 SNPs respectively.
There was no significant difference within each model for any of the
n SNP combinations (d) to (f).
Additional file 3: Table S2. SAPCS study characteristics and association
with prostate cancer risk.
Additional file 4: Table S3. Case-only analysis for association between
epidemiological measures and Gleason score.
Additional file 5: Table S4. Case-only analysis for association between
epidemiological measures and tumor grade.
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